

Table of Contents For Ex. 1015A

Certified Copy of US Provisional 60/888,921 as received by the International Bureau

WIPO Cover Letter-----	page 2
Front page -----	page 3
Provisional Application Cover Sheet -----	page 4
Specification -----	pages 5 - 40
Claims -----	pages 41 - 43
Abstract -----	page 44
Drawings -----	pages 45 - 46
Electronic Acknowledgment Receipt -----	pages 47 - 49

Coalition Exhibit 1015A

Coalition v. Biogen

IPR2015-01136

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2008/001602

International filing date: 07 February 2008 (07.02.2008)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/888,921
Filing date: 08 February 2007 (08.02.2007)

Date of receipt at the International Bureau: 26 March 2008 (26.03.2008)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS, SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 26, 2008

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/888,921


FILING DATE: February 08, 2007

RELATED PCT APPLICATION NUMBER: PCT/US08/01602

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS US60/888,921



Certified by



Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION under 37 CFR 1.53(c).

Docket Number 08201.6042-00000		Type a plus sign (+) inside this box =		+
INVENTOR(s)/APPLICANT(s)				
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (CITY AND EITHER STATE OR FOREIGN COUNTRY)	
..	
TITLE OF INVENTION (500 characters max)				
Nrf2 SCREENING ASSAYS AND RELATED METHODS AND COMPOSITIONS				
CORRESPONDENCE ADDRESS				
BIOGEN IDEC / FINNEGAN HENDERSON, LLP			Customer Number 65,779	
ENCLOSED APPLICATION PARTS (check all that apply)				
<input checked="" type="checkbox"/> Specification: 40 Pages <input checked="" type="checkbox"/> Drawing(s): 2 Sheets/2 Figures <input type="checkbox"/> Other: [Number] Pages; [Description]				
METHOD OF PAYMENT				
<input type="checkbox"/> A check or money order is enclosed to cover the Provisional Application filing fees		PROVISIONAL FILING FEE \$200.00 Total Number of Pages of specification, drawings, sequence or computer listing, or other papers 42. If more than 100 pages, add \$250 for each additional 50 pages or fraction thereof.		
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any deficiency or credit any overpayment in fees to Deposit Account Number 06-0916.		TOTAL FILING FEE \$200.00		

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are:

[Text]

Respectfully submitted on behalf of the patent practitioners associated with Customer Number 65,779.

SIGNATURE 

Date February 8, 2007

TYPED OR PRINTED NAME Konstantin M. Linnik

REGISTRATION NO. 56,309

Additional inventors are being named on separately numbered sheets attached hereto.

PROVISIONAL APPLICATION FILING ONLY

**Nrf2 SCREENING ASSAYS
AND RELATED METHODS AND COMPOSITIONS**

[0001] The invention relates to the field of cell and molecular biology and to the development and use of therapeutic compounds, more particularly, compounds for treating neurological diseases, including demyelinating neurological diseases, such as, e.g., multiple sclerosis.

[0002] Multiple sclerosis (MS) is an autoimmune disease with the autoimmune activity directed against central nervous system (CNS) antigens. The disease is characterized by inflammation in parts of the CNS, leading to the loss of the myelin sheathing around neuronal axons (demyelination), loss of axons, and the eventual death of neurons, oligodendrocytes and glial cells.

[0003] An estimated 2,500,000 people in the world suffer from MS. It is one of the most common diseases of the CNS in young adults. MS is a chronic, progressing, disabling disease, which generally strikes its victims some time after adolescence, with diagnosis generally made between 20 and 40 years of age, although onset may occur earlier. The disease is not directly hereditary, although genetic susceptibility plays a part in its development.

Relapsing-remitting MS presents in the form of recurrent attacks of focal or multifocal neurologic dysfunction. Attacks may occur, remit, and recur, seemingly randomly over many years. Remission is often incomplete and as one attack follows another, a stepwise downward progression ensues with increasing permanent neurological deficit.

[0004] Although various immunotherapeutic drugs can provide relief in patients with MS, none is capable of reversing disease progression, and some can cause serious adverse effects. Most current therapies for MS are aimed at the reduction of inflammation and suppression or modulation of the immune system. As of 2006, the available treatments for MS reduce inflammation and the number of new episodes but not all have an effect on disease progression. A number of clinical trials have shown that the suppression of inflammation in chronic MS rarely significantly limits the accumulation of disability through

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.